Aims: Hepatic
fibrosis results from chronic liver injury and inflammatory responses. Sestrin 2 (Sesn2), an evolutionarily conserved
antioxidant enzyme, reduces the severities of acute
hepatitis and metabolic
liver diseases. However, the role of Sesn2 in the pathogenesis of
liver fibrosis remains obscure. Here, we used cultured hepatic stellate cells (HSCs) and chronic
carbon tetrachloride (CCl4) and bile duct
ligation (BDL) murine models to investigate the effects of Sesn2 on fibrogenesis. Results: Sesn2
protein and
mRNA levels were upregulated in activated primary HSCs, and by increasing transcription,
transforming growth factor-β (TGF-β) also increased Sesn2 expression in HSCs. Furthermore, Smad activation was primarily initiated by TGF-β signaling, and Smad3 activation increased Sesn2
luciferase activity. In silico analysis of the 5' upstream region of the Sesn2 gene revealed a putative Smad-binding
element (SBE), and its deletion demonstrated that the SBE between -964 and -956 bp within human Sesn2 promoter was critically required for TGF-β-mediated response. Moreover, ectopic expression of Sesn2 reduced gene expressions associated with HSC activation, and this was accompanied by marked decreases in SBE
luciferase activity and Smad phosphorylation.
Infection of recombinant adenovirus Sesn2 reduced hepatic injury severity, as evidenced by reductions in CCl4- or BDL-induced
alanine aminotransferase and
aspartate aminotransferase, and inhibited
collagen accumulation. Furthermore, HSC-specific lentiviral delivery of Sesn2 prevented CCl4-induced
liver fibrosis. Finally, Sesn2 expression was downregulated in the livers of patients with
liver cirrhosis and in mouse models of hepatic
fibrosis. Innovation and Conclusion: Our findings suggest that Sesn2 has the potential to inhibit HSC activation and hepatic
fibrosis.